Florence Neal Cooper Smith Sickle Cell Research Endowment Fund; established.
Summary
HB2500 creates the Florence Neal Cooper Smith Sickle Cell Research Endowment Fund in the state treasury. The fund is designated as a special, nonreverting, revolving, and permanent account administered by the Board, with money coming from legislative appropriations and from gifts, grants, or donations from public or private sources. Interest earned stays in the fund, and unspent balances do not revert to the general fund at the end of the fiscal year.
The bill directs the fund to support medical and biomedical sickle cell disease research at institutions of higher education in Virginia, specifically research related to the causes and cures of sickle cell disease. It also authorizes the Board to set criteria and procedures for awarding grants, allows support for research that may not qualify for federal NIH funding if justified, and prohibits funding for human sickle cell research using embryonic stem cells while allowing research using non-embryonic stem cells. The bill is named to honor Florence Neal Cooper Smith and reflects her role in sickle cell awareness and newborn screening efforts in Virginia.
Impact
HB2500 amends the Code of Virginia by adding a new section in Title 32.1 establishing a dedicated state fund for sickle cell research. It creates a new fiscal mechanism for directing public and private money to Virginia higher education institutions for research on sickle cell disease, and it exempts the fund from reverting to the general fund. The bill also imposes substantive restrictions on eligible research, including a ban on funding embryonic stem cell-based human sickle cell research, while leaving administration and grant criteria to the Board.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It advanced unanimously through a subcommittee, the Appropriations and Finance committees, and both chambers, with recorded votes of 7-0, 22-0, 96-0, 15-0, 40-0, and 36-0. The vote pattern suggests strong agreement with the bill’s public health and research goals, as well as with the memorialization of Florence Neal Cooper Smith.
Contention
There is little evidence of controversy in the available record, but the bill does contain a notable policy limitation: it bars funding for human sickle cell disease research involving embryonic stem cells. That restriction could be a point of concern for researchers or advocates who favor broader biomedical research options. Another possible issue is that the fund depends on appropriations and donations, so its practical impact will depend on future funding levels and the Board’s grant criteria, though no opposition appears in the recorded votes.